Loading
Antitumor Immunity · Journal article
International Journal of Pharmaceutics: X · July 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical mechanistic study of a multi-component zinc and STING-agonist nanoplatform (PT-c-di-GMP/OVA@ZIF-8) designed to enhance antitumor immunity in prostate cancer models. Both laboratory and animal experiments showed tumor regression and enhanced immune activation, with synergy demonstrated when combined with anti-PD-L1 antibody; however, no clinical efficacy or safety data in human subjects are reported.
Preclinical experimental study (in vitro and in vivo). Prostate cancer cell lines and animal tumor models; no human subjects enrolled.. Intervention: Nanoplatform PT-c-di-GMP/OVA@ZIF-8 encapsulating pyrithione (Zn2+ ionophore), cyclic diguanylate (STING agonist), and ovalbumin (antigen), with and without anti-PD-L1 antibody.. Compared with: Anti-PD-L1 antibody combination tested; no untreated or alternative control explicitly stated in abstract..
PT-c-di-GMP/OVA@ZIF-8 effectively activates STING signaling and antitumor immune responses, leading to tumor regression in both in vitro and in vivo experiments. Combination therapy with anti-PD-L1 antibody further enhanced antitumor efficacy. Nanoplatform demonstrated a favorable safety profile in preclinical models.
Safety profile described as 'favorable' but specific toxicity data not detailed. Nanoplatform demonstrated a favorable safety profile in preclinical models.
This preclinical evidence suggests a potential immunotherapeutic strategy for prostate cancer, but clinical translation requires investigational new drug (IND)-enabling studies and human trials before any practice recommendation can be made.
Preclinical in vitro and in vivo study of a novel nanoplatform in experimental models; no clinical trials or human data reported; mechanism-focused work showing promise but not yet tested in patients.
As stated by the source record.
This preclinical evidence suggests a potential immunotherapeutic strategy for prostate cancer, but clinical translation requires investigational new drug (IND)-enabling studies and human trials before any practice recommendation can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Zinc homeostasis dysregulation is a significant feature in prostate cancer (PCa), characterized by a marked decrease in intracellular Zn2+ concentration. High levels of Zn2+ inhibit PCa cell proliferation, enhance drug sensitivity, and are closely linked to antitumor immune activation. Here, zeolitic imidazolate framework-8 (ZIF-8) was employed to encapsulate pyrithione (PT), a Zn2+ ionophore, and cyclic diguanylate (c-di-GMP), a STING agonist, followed by encapsulation with ovalbumin (OVA). In this nanoplatform (PT-c-di-GMP/OVA@ZIF-8), ZIF-8 degrades within the tumor microenvironment (TME) to release Zn2+. Upon cellular uptake, PT facilitates the intracellular transport of extracellular Zn2+. These Zn2+ may act synergistically with c-di-GMP to stimulate the cGAS-STING pathway, while OVA promoting antigen presentation, collectively activating and amplifying antitumor immunity. Both in vitro and in vivo experiments demonstrated that PT-c-di-GMP/OVA@ZIF-8 effectively activates STING signaling and antitumor immune responses, leading to tumor regression. Furthermore, combination therapy with an anti-PD-L1 antibody further enhanced the antitumor efficacy. This study proposes a Zn2+ overload and cGAS-STING pathway-based nanoplatform that activates robust antitumor immunity with a favorable safety profile, showing promise as a candidate strategy for PCa treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.